Omeros Corporation (NASDAQ:OMER)‘s stock had its “buy” rating reaffirmed by research analysts at Maxim Group in a research report issued on Friday. They currently have a $24.00 price objective on the biopharmaceutical company’s stock. Maxim Group’s price objective indicates a potential upside of 55.24% from the stock’s current price.

A number of other research analysts also recently commented on OMER. Zacks Investment Research downgraded shares of Omeros Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday. Wedbush reissued an “outperform” rating and set a $47.00 target price on shares of Omeros Corporation in a research report on Friday, August 18th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $19.00 target price (up previously from $15.00) on shares of Omeros Corporation in a research report on Thursday, August 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $34.83.

Shares of Omeros Corporation (OMER) traded up 11.87% during midday trading on Friday, reaching $15.46. 1,511,109 shares of the company’s stock were exchanged. Omeros Corporation has a 12-month low of $7.80 and a 12-month high of $27.09. The company’s market cap is $692.65 million. The stock’s 50 day moving average price is $20.40 and its 200 day moving average price is $19.52.

Omeros Corporation (NASDAQ:OMER) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.12. The business had revenue of $17.15 million for the quarter, compared to analysts’ expectations of $14.63 million. The company’s revenue for the quarter was up 71.5% on a year-over-year basis. During the same period last year, the business posted ($0.32) EPS. Equities analysts anticipate that Omeros Corporation will post ($1.30) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Maxim Group Reiterates Buy Rating for Omeros Corporation (OMER)” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/27/maxim-group-reiterates-buy-rating-for-omeros-corporation-omer.html.

Institutional investors have recently modified their holdings of the company. Mesirow Financial Investment Management Inc. purchased a new position in shares of Omeros Corporation in the 2nd quarter worth approximately $456,000. Bank of New York Mellon Corp grew its position in shares of Omeros Corporation by 2.8% in the 1st quarter. Bank of New York Mellon Corp now owns 225,583 shares of the biopharmaceutical company’s stock worth $3,411,000 after buying an additional 6,043 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Omeros Corporation by 5.5% in the 1st quarter. Wells Fargo & Company MN now owns 37,717 shares of the biopharmaceutical company’s stock worth $571,000 after buying an additional 1,960 shares during the last quarter. Swiss National Bank grew its position in shares of Omeros Corporation by 5.7% in the 1st quarter. Swiss National Bank now owns 67,100 shares of the biopharmaceutical company’s stock worth $1,015,000 after buying an additional 3,600 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in shares of Omeros Corporation by 66.2% in the 2nd quarter. Teachers Advisors LLC now owns 113,509 shares of the biopharmaceutical company’s stock worth $2,259,000 after buying an additional 45,224 shares during the last quarter. 44.87% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.